Stordeur
Guillaume Stordeur, Plainsboro, NJ US
Patent application number | Description | Published |
---|---|---|
20120235998 | Three-Dimensional Reconstruction for Irregular Ultrasound Sampling Grids - An irregular ultrasound sampling grid is reconstructed to a three-dimensional grid for imaging. Volume data acquired with a helix transducer includes a fractional offset of data spaced along one dimension, resulting in the irregular ultrasound sampling grid. To determine a voxel value for a grid point on a uniform grid, two adjacent planes are identified. The sample locations in the two planes are not aligned, being on the irregular ultrasound sampling grid. Hardware acceleration devices, such as a graphics processing unit, perform bilinear interpolation in each of the planes. The data of each plane is interpolated to the proper global azimuth-range coordinate corresponding with the grid point. The bilinearly interpolated values from each plane are then linearly interpolated to the grid point. | 09-20-2012 |
Patrick Stordeur, Forest BE
Patent application number | Description | Published |
---|---|---|
20100129788 | METHOD FOR EVALUATING THE RESPONSE OF AN INDIVIDUAL TO A TREATMENT WITH A TYPE I INTERFERON (IFN) - A method for evaluating the in vivo presence of a factor that prevents the biological effect of a type I (IFN) in an individual that is under treatment with type I interferon is described. The in vivo presence of antibodies directed against a type I interferon (IFN) is evaluated in an individual that is under treatment with type I interferon. The method includes incubating a blood sample of the individual in vitro with a suitable amount of the type I interferon for a suitable period of time, and determining mRNA levels of a biological marker of IFN activity, preferably M×A, in the blood sample. The treatment may involve a treatment of multiple sclerosis, HCV or HBV using a type I interferon. | 05-27-2010 |
20120190031 | MARKER FOR DIAGNOSIS OF ACTIVE MULTIPLE SCLEROSIS - The invention provides an improved method for monitoring the course of the MS disease and to predict, diagnose or prognosticate whether a subject is in an active or non-active period of MS. The method is based on determining the ratio of the expression levels of two cytokines, measured before and after stimulation of the subject by an immunomodulator. | 07-26-2012 |
Patrick Stordeur, Charleroi BE
Patent application number | Description | Published |
---|---|---|
20090297474 | Method for Detecting or Monitoring Sepsis by Analysing Cytokine mRNA Expression Levels - The present invention relates to a method for identifying patients who are likely to develop sepsis in response to infection, a method for monitoring the progress of sepsis in a patient and to an assay kit for identifying patients who are likely to develop sepsis and/or monitoring the progress of sepsis. | 12-03-2009 |
20130040299 | METHOD FOR DETECTING OR MONITORING SEPSIS BY ANALYSING CYTOKINE MRNA EXPRESSION LEVELS - The present invention relates to a method for identifying patients who are likely to develop sepsis in response to infection, a method for monitoring the progress of sepsis in a patient and to an assay kit for identifying patients who are likely to develop sepsis and/or monitoring the progress of sepsis. | 02-14-2013 |
Patrick Stordeur, Bruxelles BE
Patent application number | Description | Published |
---|---|---|
20090117646 | DEVICE, KIT AND METHOD FOR PULSING BIOLOGICAL SAMPLES WITH AN AGENT AND STABILISING THE SAMPLE SO PULSED - A device and kit for pulsing a biological sample with a pulsing agent is disclosed. The biological sample so pulsed is subsequently stabilized and the device or kit provides a control reaction. Applications for the described device and kit are found in the field of medical diagnostics, particularly immunology. | 05-07-2009 |
20110129839 | DEVICE, KIT AND METHOD FOR PULSING BIOLOGICAL SAMPLES WITH AN AGENT AND STABILISING THE SAMPLE SO PULSED - The present invention is related to a device, kit and method for pulsing a biological sample with a pulsing agent and subsequently stabilizing the biological sample so pulsed. The invention has application in the fields of medical diagnostics, particularly relating to immunity. | 06-02-2011 |
20110263007 | DEVICE, KIT AND METHOD FOR PULSING BIOLOGICAL SAMPLES WITH AN AGENT AND STABILISING THE SAMPLE SO PULSED - A device and kit for pulsing a biological sample with a pulsing agent is disclosed. The biological sample so pulsed is subsequently stabilized and the device or kit provides a control reaction. Applications for the described device and kit are found in the field of medical diagnostics, particularly immunology. | 10-27-2011 |
Patrick Stordeur, Dublin IE
Patent application number | Description | Published |
---|---|---|
20120129176 | CYTOKINES AS PROGNOSTIC MARKERS OF RESPIRATORY-TRACT INFECTION FOLLOWING MAJOR SURGERY - The invention relates to the use of a certain subset of cytokine markers as prognostic variables of infection status in an individual, and especially as prognostic markers of a patients developing severe infection such as pneumonia, and respiratory tract infection following surgery. The subset of cytokine markers consists of the interleukin cytokines IL-2, IL-7, IL-23, IL-27, and IL-IO, and Interferon-γ (INFγ) and Tissue Necrosis Factor-α (TNFα). The markers may be employed as individual prognostic variables of infection status, or they may be used in pairs or other combinations. Generally, the abundance of the markers is correlated with infection status by means of an absolute pre-operative value of biomarker abundance, ratio's of pre-operative to post-operative biomarker abundance, or ratio values for pairs of certain biomarkers within the subset. Typically, cytokine abundance is expressed in terms of mRNA copy number wherein the copy numbers are ideally normalised to a house keeping gene and quantification of mRNA copy number is determined by RT-PCR containing reference serial dilutions of cytokine specific cDNA. | 05-24-2012 |